VRDN

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET. Conference Call and.

The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Viridian Therapeutics delivered a strong Q3, with Lumvoa net sales of $24.7 million, far surpassing consensus expectations. Competition is intensifying with Roche's Enspryng entering the TED market, but I see Lumvoa as well-positioned for continued growth, with more growth expected to come from elegrobart in late 2027. VRDN's near-term focus is on phase 1 data for VRDN-008 in the FcRn franchise, with expectations for deep IgG lowering and good safety and tolerability.

Viridian Therapeutics NASDAQ: VRDN reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment's first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30.

Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $0.34 per share a year ago.

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026. Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A w.

Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency. The current valuation is demanding, with no near-term asset-based floor; future profitability hinges on successful commercialization and infrastructure sharing.

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Invest.

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve.